Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

ONCY Common Stock Issued

Cash raised by issuing new shares.

Oncolytics Biotech Inc.NASDAQ: ONCY

Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026

Common stock issued grows, but more slowly than its trailing trend

Q1 FY2026 common stock issued of CA$10.62M rose 77.2% year over year, behind the +140.6% change in trailing-twelve-month common stock issued. Sequentially, it rose 54.1% from the prior quarter. Over 3 fiscal years it compounded at +15.6% a year.

Context

  • Common stock issued increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +77.2% toward the trailing-twelve-month pace of +140.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$10.62M+54.1% QoQ
Last fiscal yearDec 2025
CA$19.41M+180.6% YoY
LTMMar 2026
CA$27.22M+140.6% YoY
Common Stock Issued past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+77.2%——
1 year+180.6%——
3-year CAGR+15.6%——
5-year CAGR——
10-year CAGR——

Common Stock Issued history

CAD · from the cash flow

Latest · FY2025
19.41M CAD
Year-over-year change
+180.6%
4-year CAGR
-12.4%

Common Stock Issued vs competitors

How ONCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so common stock issued is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +140.6% is the highest of 7, against a peer median of -80.0%.
  • Over three fiscal years its annual growth of +15.6% compares with a peer median of +11.3%.
ONCY Competitors
Common Stock Issued for ONCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WHWKWhitehawk Therapeutics IncLTM Dec 2025$204.8M USD—+11.3%2866.4%
IMMXImmix Biopharma, Inc.LTM Mar 2026$107.36M USD—+216.5%—
SRZNSurrozen, Inc.LTM Mar 2026$38.89M USD-58.0%+1165.2%518.9%
COYACoya Therapeutics, Inc.LTM Mar 2026$31.36M USD+114.2%+4950.0%395.1%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$27.22M CAD+140.6%+15.6%—
TILInstil Bio, Inc.LTM Mar 2026$6.23M USD-910.5%-18.0%—
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$4.14M USD-1527.6%——
CLNNClene Inc.LTM Mar 2026$2.66M USD-77.7%-3.2%1984.3%
MGNXMacroGenics, Inc.LTM Mar 2026$140K USD-82.4%-50.8%0.1%
Peer median (excluding ONCY) —-80.0%+11.3%518.9%

Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.3M)(24.84M)(27.75M)(31.71M)(39.46M)
Depreciation & Amortization452.07K392K403K424K96.05K
Deferred Income Tax408.56K0000
Stock-Based Compensation3.83M2.38M2.07M2.72M4.26M
Change in Working Capital(907.99K)391K1.77M3.54M1.62M
Accounts Receivables(776.39K)345K506K(53K)4.03M
Inventory00000
Accounts Payables00000
Other Working Capital(131.59K)46K1.26M3.59M(2.41M)
Other Non-Cash Items91.73K(1.68M)(4.93M)(1.94M)5.89M
Operating Cash Flow(22.43M)(23.36M)(28.45M)(26.97M)(27.6M)
Capital Expenditures(285.95K)(55K)(8K)(239K)(8.23K)
Acquisitions (Net)00000
Purchases of Investments0(20.35M)000
Sales of Investments0020.23M00
Other Investing Activities0(20.35K)000
Investing Cash Flow(285.95K)(20.4M)20.22M(239K)(8.23K)
Debt Repayment(366K)(381K)(407K)(348K)0
Common Stock Issued32.91M12.57M31.62M6.92M19.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities469.68K12K781K65K(37.05K)
Financing Cash Flow33.02M12.21M31.99M6.64M19.37M
Effect of Forex Changes(253.25K)1.96M(522K)1.6M166.03K
Net Change in Cash10.04M(29.6M)23.25M(18.97M)(8.06M)
Free Cash Flow(22.72M)(23.41M)(28.46M)(27.21M)(27.6M)

Oncolytics Biotech Inc.

NASDAQ:ONCY

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.